Related to Threshold Pharma Gets $20M from Merck KGaA After Phase II Success with Anticancer Agent

• Merck & Co. Picks Up Exclusive Option on Xenon CV Drugs
  
• EMD Serono Expanding R&D Hub in Billerica, MA
  
• Theravance to Split Late-Stage Partnered Assets from Biopharma R&D, Creating Two New Companies
  
• Merck Launches Up To $430M Diabetes Collaboration with Abide
  
• Celgene, Concert in $300M+ Deuterium Drug Collaboration
  
• Nimbus, Shire Collaborate to Co-Develop Small Molecule Treatments
  
• Evotec, Harvard Go on Antibacterial Drug Hunt
  
• Idera to Obtain $3.8M from Merck KGaA for Progress of Anticancer Agent
  
• PDS to Use Merck Eprova's Cationic Lipid to Enhance Preclinical Compounds
  
• Cancer Research UK to Conduct Phase I Trial with Merck KGaA’s B-Cell Lymphoma Candidate
  
• Idera Receives $4.3M with Merck KGaA’s Initiation of a Phase II Head and Neck Cancer Trial
  
• BioWa Grants Merck KGaA Access to Technology that Enhances Antibody-Dependent Cellular Cytotoxicity
  
• Lpath Bags $2M Asonep Milestone from Merck KGaA and then Severs Ties
  
• Evotec and Merck KGaA Sign Neurological Drug Discovery Deal
  
• Merck KGaA and Sanofi-Aventis to Evaluate Combinations of Phase I Anticancer Compounds
  
• Apeiron Licenses Phase II/III Anticancer Ab-IL2 Fusion Protein from Merck KGaA
  
• Merck KGaA to Use MDxHealth’s Assay in Second Clinical Glioblastoma Study
  
• Merck KGaA Returns All Rights to Anticancer TLR9 Agonists to Idera
  
• Merck KGaA Partners with European ScreeningPort on Multiple Sclerosis Research
  
• Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M